gabapentin has been researched along with haloperidol in 23 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (4.35) | 18.2507 |
2000's | 10 (43.48) | 29.6817 |
2010's | 8 (34.78) | 24.3611 |
2020's | 4 (17.39) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Peng, Y; Welsh, WJ; Zhang, Q | 1 |
Gordon, SM; Regan, WM | 1 |
Gundlapalli, SP; Iqbal, MM; Passman, TE; Ryals, T; Ryan, WG | 1 |
Klein, S; Nicolas, LB; Prinssen, EP | 1 |
Demily, C; Franck, N | 1 |
Attupurath, R; Aziz, R; Muralee, S; Tampi, RR; Wollman, D | 1 |
Espinosa-Juárez, JV; Jaramillo-Morales, OA; López-Muñoz, FJ | 1 |
Dougan, B; Kashiwagi, D; Mauck, K; Regan, DW; Sundsted, K | 1 |
Ceretta, APC; de Freitas, CM; de Moraes Reis, E; Dotto, MM; Fachinetto, R; Machado-de-Ávila, RA; Reinheimer, JB; Schaffer, LF; Scussel, R | 1 |
Rouse, S; Wodziak, M | 1 |
Déciga-Campos, M; Espinosa-Juárez, JV; Jaramillo-Morales, OA; López-Muñoz, FJ; Villafán-Gutiérrez, R | 1 |
Akgül, E; Engin, EF; Ertan Akan, G; Polat, B | 1 |
Li, H; Li, P; Li, S; Wang, R | 1 |
5 review(s) available for gabapentin and haloperidol
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Effects of antimanic mood-stabilizing drugs on fetuses, neonates, and nursing infants.
Topics: Abnormalities, Drug-Induced; Acetates; Adult; Amines; Antimanic Agents; Benzodiazepines; Breast Feeding; Carbamazepine; Cyclohexanecarboxylic Acids; Female; Fetus; Gabapentin; gamma-Aminobutyric Acid; Haloperidol; Humans; Infant, Newborn; Lithium; Mood Disorders; Olanzapine; Pirenzepine; Placenta; Pregnancy; Risk Factors; Valproic Acid | 2001 |
Update in perioperative medicine: practice changing evidence published in 2016.
Topics: Amines; Analgesics; Anticoagulants; Antipsychotic Agents; Arthritis, Rheumatoid; Blood Transfusion; Cyclohexanecarboxylic Acids; Cyclooxygenase 2 Inhibitors; Delirium; Disease Progression; Evidence-Based Practice; Gabapentin; gamma-Aminobutyric Acid; Haloperidol; Hemorrhage; Humans; Pain, Postoperative; Perioperative Care; Postoperative Complications; Practice Guidelines as Topic; Risk Assessment; Surgical Wound Infection; Thromboembolism; Tumor Necrosis Factor-alpha | 2017 |
Intractable Hiccups.
Topics: Anticonvulsants; Dopamine Antagonists; Gabapentin; Haloperidol; Hiccup; Humans | 2018 |
Different interventions for preventing postoperative catheter-related bladder discomfort: a systematic review and meta-analysis.
Topics: Chlorpheniramine; Dexmedetomidine; Gabapentin; Haloperidol; Humans; Ketamine; Lidocaine; Meperidine; Nefopam; Pain, Postoperative; Pregabalin; Tolterodine Tartrate; Tramadol; Urinary Bladder; Urinary Catheters | 2022 |
18 other study(ies) available for gabapentin and haloperidol
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Novel Sigma 1 Receptor Antagonists as Potential Therapeutics for Pain Management.
Topics: Animals; Binding Sites; Blood-Brain Barrier; Drug Design; Guinea Pigs; Half-Life; Humans; Microsomes, Liver; Molecular Dynamics Simulation; Neuralgia; Pain Management; Protein Structure, Tertiary; Quantitative Structure-Activity Relationship; Rats; Receptors, sigma; Sigma-1 Receptor; Triazoles | 2021 |
Gabapentin for behavioral agitation in Alzheimer's disease.
Topics: Acetates; Aged; Alzheimer Disease; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Administration Schedule; Drug Therapy, Combination; Female; Gabapentin; gamma-Aminobutyric Acid; Haloperidol; Humans; Psychomotor Agitation; Treatment Outcome | 1997 |
Defensive-like behaviors induced by ultrasound: further pharmacological characterization in Lister-hooded rats.
Topics: Amines; Analgesics, Opioid; Animals; Anti-Anxiety Agents; Bridged Bicyclo Compounds; Buspirone; Calcium Channel Blockers; Cyclohexanecarboxylic Acids; Diazepam; Dose-Response Relationship, Drug; Escape Reaction; Fear; Freezing Reaction, Cataleptic; Gabapentin; gamma-Aminobutyric Acid; Haloperidol; Imidazoles; Male; Morphine; Motor Activity; Nociceptin Receptor; Pregabalin; Pyridines; Rats; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Receptors, Opioid; Spiro Compounds; Thiazoles; Ultrasonics | 2007 |
Gabapentin for ultra resistant schizophrenia with aggressive behavior.
Topics: Adult; Aggression; Amines; Anticonvulsants; Antipsychotic Agents; Cyclohexanecarboxylic Acids; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Gabapentin; gamma-Aminobutyric Acid; Haloperidol; Humans; Male; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Violence | 2008 |
Chorea associated with gabapentin use in an elderly man.
Topics: Aged; Amines; Analgesics; Anti-Dyskinesia Agents; Anxiety; Chorea; Cognition Disorders; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Haloperidol; Humans; Magnetic Resonance Imaging; Male; Memory Disorders; Neuropsychological Tests | 2009 |
Haloperidol Decreases Hyperalgesia and Allodynia Induced by Chronic Constriction Injury.
Topics: Amines; Analgesics; Animals; Antipsychotic Agents; Chronic Disease; Constriction, Pathologic; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Gabapentin; gamma-Aminobutyric Acid; Haloperidol; Hyperalgesia; Injections, Spinal; Male; Neuralgia; Pain Measurement; Piperazines; Rats; Rats, Wistar; Receptors, sigma; Sigma-1 Receptor; Sulpiride | 2017 |
Gabapentin reduces haloperidol-induced vacuous chewing movements in mice.
Topics: Animals; Anti-Anxiety Agents; Anti-Dyskinesia Agents; Dopamine Antagonists; GABA Modulators; Gabapentin; Haloperidol; Male; Mastication; Mice | 2018 |
Synergistic interaction between haloperidol and gabapentin in a model of neuropathic nociception in rat.
Topics: Analgesics; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Gabapentin; Haloperidol; Hyperalgesia; Male; Nociception; Nociceptive Pain; Rats, Wistar; Receptors, sigma; Sciatica; Sigma-1 Receptor; Signal Transduction | 2021 |
Cerebral proliferative angiopathy accompanied by cerebral cavernous malformation: A case report.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Cerebral Small Vessel Diseases; Gabapentin; Haloperidol; Hemangioma, Cavernous, Central Nervous System; Humans; Male | 2021 |